Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

81
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
81
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

113
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
113
Hazard Ratio01:12

Hazard Ratio

73
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
73
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

110
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
110
Introduction To Survival Analysis01:18

Introduction To Survival Analysis

150
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
150
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

74
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
74

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Democratizing computational skills: evaluating an asynchronous microlearning framework for cloud-based data analytics in health services research.

Frontiers in public health·2026
Same author

Building Capacity for Rigorous Health Research Through Grant Writing Coaching.

International journal of environmental research and public health·2026
Same author

The NIH Research Centers in Minority Institutions (RCMI): National and Public Health Impact as Measured by Collaborative Scientific Excellence, Investigator Development, and Community Engagement.

International journal of environmental research and public health·2025
Same author

Feasibility of nephrology electronic consults in an inner-city population.

Clinical nephrology·2025
Same author

Exploring grant writing coaching and its role in professional development of health equity investigators: A qualitative study.

Journal of clinical and translational science·2025
Same author

Revolutionizing Oncology Through AI: Addressing Cancer Disparities by Improving Screening, Treatment, and Survival Outcomes via Integration of Social Determinants of Health.

Cancers·2025

Related Experiment Video

Updated: May 22, 2025

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.1K

Simulations-Based Least Required Sample Size and Power in Clinical Trials with Time-to-Event endpoint and Variable

Mohamed Mubasher1, Liang Shan2, Fengxia Yan1

  • 1Community Health and Preventive Medicine Department Morehouse School of Medicine, Atlanta GA.

International Journal of Epidemiology and Public Health Research
|May 20, 2025
PubMed
Summary

This study determined optimal sample size and power for clinical trials by simulating time-to-event data with varying hazard rates. Findings guide efficient trial design for accurate event rate analysis.

Keywords:
HazardSimulationStatistical PowerTime-to-eventWeibull

More Related Videos

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.0K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.3K

Related Experiment Videos

Last Updated: May 22, 2025

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.1K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.0K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.3K

Area of Science:

  • Clinical Trials
  • Biostatistics
  • Survival Analysis

Background:

  • Sample size and statistical power are critical for clinical trial design with time-to-event outcomes.
  • The hazard function, describing event occurrence rates over time, is key but can vary (constant, decreasing, increasing).

Purpose of the Study:

  • To determine minimum sample size and power requirements for clinical trials.
  • To investigate the impact of different hazard function patterns on these parameters.
  • To provide guidance for robust clinical trial planning.

Main Methods:

  • Simulated two independent samples of time-to-event data using the Weibull distribution.
  • Varied hazard patterns (constant, decreasing, increasing), scale parameters, and follow-up durations.
  • Analyzed simulated data to assess sample size and power needs.

Main Results:

  • Identified specific sample size and power combinations effective across different Weibull hazard scenarios.
  • Demonstrated the influence of hazard function characteristics on required statistical power.
  • Quantified the impact of varying scale parameters and follow-up periods on trial design.

Conclusions:

  • The Weibull distribution effectively models variable hazard functions in time-to-event analyses.
  • Simulation-based approaches are valuable for optimizing clinical trial sample size and power.
  • Accurate characterization of hazard patterns is essential for efficient clinical trial design.